Innate Pharma is a clinical-stage biopharmaceutical company based in France that develops antibody-based treatments for cancer. Its work centres on immunotherapies designed to harness the body's immune system against tumours, with drug candidates studied in blood cancers and solid tumours. The company carries out its own research and also works with larger pharmaceutical partners on the development of its programmes. Its customers are chiefly the clinical and research institutions and corporate collaborators involved in testing and advancing these experimental medicines.
The shares are listed on the London Exchange in UK under the code 0EVI, and the price on this page is in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Weak price profile
Ranks #3101 of 3787 on the London Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for UK yet.
TrendWeak
35/100
Below its long-term averages and far from its highs.
See the numbers →
Above 200-day average-13.0%
From 52-week high-41.4%
MomentumWeak
37/100
Lagging most stocks on this exchange.
See the numbers →
3-month return-18.2%
6-month return10.3%
12-month, skipping last month-14.5%
Stability (higher is calmer)Weak
21/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)65.9%
Worst drawdown, 1 year (smaller is calmer)-43.7%
LiquidityWeak
22/100
Thinly traded: prices can jump and exits can be hard.
See the numbers →
Avg daily value traded0.04M EUR
Zero-volume days11.7%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for UK when fundamentals data for this market is added. All UK stocks.
52-wk range 1.040 – 2.330Daily closes, split-adjusted
Signals
50-day average1.549
200-day average1.484
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.359
Technical summary
Daily
Strongly bearish
2 bullish · 1 neutral · 13 bearish
Weekly
Strongly bearish
0 bullish · 1 neutral · 11 bearish
Monthly
Strongly bearish
0 bullish · 1 neutral · 7 bearish
Moving averages (daily)
SMA 10
1.29
Bearish
EMA 10
1.31
Bearish
SMA 20
1.32
Bearish
EMA 20
1.35
Bearish
SMA 50
1.55
Bearish
EMA 50
1.46
Bearish
SMA 100
1.58
Bearish
EMA 100
1.52
Bearish
SMA 200
1.48
Bearish
EMA 200
1.54
Bearish
Oscillators (daily)
RSI (14)
38.17
Neutral
MACD (12, 26)
-0.06
Bearish
Momentum (12)
-2.20
Bearish
Stochastic %K (14)
4.18
Bullish
Williams %R (14)
-95.82
Bullish
CCI (20)
103.7
Bearish
Pivot points (classic, last session)
S3
0.07
S2
0.68
S1
0.99
Pivot
1.60
R1
1.90
R2
2.52
R3
2.82
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in EUR. Educational only, not financial advice.
